Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: Case report and review of the literature

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 4, 2006, Pages 401-406

  Kim, K B ^a   Fader, S ^a   Hwang, C S ^b   Khuri, F R ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b Houston   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myelomonocytic leukaemia; Leukaemia; Myelodysplastic syndrome; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; GEMCITABINE; HYDROXYUREA; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RUBITECAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; TREATMENT RESPONSE; TRISOMY 8;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; ETOPOSIDE; FATAL OUTCOME; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 33745942308     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00748.x     Document Type: Article

References (39)

1. Tefferi A, Hoagland HC, Therneau TM, Pierre RV (1989) Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clinical Proceedings, 64, 1246-1254.
2. Muroi K, Miyata T, Saito M, Hatake K, Amemiya Y, Miura Y (1996) Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14). Acta Haematology, 96, 251-254.
3. Farhi DC, Odell CA, Shurin SB (1993) Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood. American Journal of Clinical Pathology, 100, 270-275.
4. Natazuka T, Yamaguchi T, Murayama T et al. (1994) Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma. International Journal of Hematology, 60, 263-265.
5. Ueki K, Sato S, Tamura J et al. (1991) Three cases of multiple myeloma developing into melphalan-related chronic myelomonocytic leukemia. Journal of Medicine, 22, 157-161.
6. Leone G, Mele L, Pulsoni A, Equitani F, Pagano L (1999) The incidence of secondary leukemias. Haematologica, 84, 937-945.
7. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. New England Journal of Medicine, 322, 1425-1429.
8. DeMent SH, Eggleston JC, Spivak JL (1985) Association between mediastinal germ cell tumors and hematologic malignancies. Report of two cases and review of the literature. American Journal of Surgical Pathology, 9, 23-30.
9. Arseneau JC, Sponzo RW, Levin DL et al. (1972) Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. New England Journal of Medicine, 287, 1119-1122.
10. Coleman CN, Williams CJ, Flint A, Glatstein EJ, Rosenberg SA, Kaplan HS (1977) Hematologic neoplasia in patients treated for Hodgkin's disease. New England Journal of Medicine, 297, 1249-1252.
11. Greene MH, Boice JD Jr, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. New England Journal of Medicine, 307, 1416-1421.
12. Boice JD Jr, Greene MH, Killen JY Jr et al. (1983) Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). New England Journal of Medicine, 309, 1079-1084.
13. Pedersen-Bjergaard J, Ersboll J, Sorensen HM et al. (1985) Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Annals of Internal Medicine, 103, 195-200.
14. Kyle RA, Pierre RV, Bayrd ED (1975) Multiple myeloma and acute leukemia associated with alkylating agents. Archives of Internal Medicine, 135, 185-192.
15. Kantarjian HM, Keating MJ (1987) Therapy-related leukemia and myelodysplastic syndrome. Seminars in Oncology, 14, 435-443.
16. Ellis M, Ravid M, Lishner M (1993) A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leukemia and Lymphoma, 11, 9-13.
17. Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Seminars in Oncology, 19, 47-84.
18. Rowley JD, Golomb HM, Vardiman JW (1981) Non-random chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood, 58, 759-767.
19. Ratain MJ, Kaminer LS, Bitran JD et al. (1987) Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood, 70, 1412-1417.
20. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M (1991) Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours [see comments]. Lancet, 338, 359-363.
21. Saso R, Kulkarni S, Mitchell P et al. (2000) Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. British Journal of Cancer, 83, 91-94.
22. Hawkins MM, Wilson LM, Stovall MA et al. (1992) Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ, 304, 951-958.
23. Bredeson CN, Barnett MJ, Horsman DE, Dalal BI, Ragaz J, Phillips GL (1993) Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. Leukemia and Lymphoma, 11, 141-145.
24. Pedersen-Bjergaard J, Philip P (1991) Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood, 78, 1147-1148.
25. Hoffmann L, Moller P, Pedersen-Bjergaard J, Waage A, Pedersen M, Hirsch FR (1995) Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature [see comments]. Annals of Oncology, 6, 781-788.
26. Dissing M, Le Beau MM, Pedersen-Bjergaard J (1998) Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? Journal of Clinical Oncology, 16, 1890-1896.
27. DeVore R, Whitlock J, Hainsworth JD, Johnson DH (1989) Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Annals of Internal Medicine, 110, 740-742.
28. Pui CH, Ribeiro RC, Hancock ML et al. (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New England Journal of Medicine, 325, 1682-1687.
29. Bradley MO, Hsu IC, Harris CC (1979) Relationship between sister chromatid exchange and mutagenicity, toxicity and DNA damage. Nature, 282, 318-320.
30. Zwelling LA, Bradley MO, Sharkey NA, Anderson T, Kohn KW (1979) Mutagenicity, cytotoxicity and DNA crosslinking in V79 Chinese hamster cells treated with cis- and trans-Pt(II) diamminedichloride. Mutation Research, 67, 271-280.
31. Chibber R, Ord MJ (1989) The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin. European Journal of Cancer Clinical Oncology, 25, 27-33.
32. Greene MH (1992) Is cisplatin a human carcinogen? Journal of the National Cancer Institute, 84, 306-312.
33. Bassett WB, Weiss RB (1986) Acute leukemia following cisplatin for bladder cancer [letter]. Journal of Clinical Oncology, 4, 614.
34. Kaldor JM, Day NE, Pettersson F et al. (1990) Leukemia following chemotherapy for ovarian cancer [see comments]. New England Journal of Medicine, 322, 1-6.
35. Philpott NJ, Elebute MO, Powles R et al. (1996) Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. British Journal of Haematology, 93, 884-887.
36. Colon-Otero G, Malkasian GD, Edmonson JH (1993) Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer. Journal of the National Cancer Institute, 85, 1858-1860.
37. Travis LB, Holowaty EJ, Bergfeldt K et al. (1999) Risk of leukemia after platinum-based chemotherapy for ovarian cancer. New England Journal of Medicine, 340, 351-357.
38. Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM (1999) Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia, 13, 1735-1740.
39. Heim S (1992) Cytogenetic findings in primary and secondary MDS. Leukemia Research, 16, 43-46.